About the THRIVE Study
About the THRIVE Clinical Study
Viridian Therapeutics is developing VRDN-001 as a potential new treatment for people living with TED. VRDN-001 is an investigational study drug that can be used only in the setting of a clinical study.
THRIVE
THRIVE is an ongoing clinical study of a potential treatment for people who have been diagnosed with moderate to severe active TED and began experiencing symptoms within the past 15 months.